A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

ALS (amyotrophic lateral sclerosis) is a fatal neurodegenerative disease that gradually affects a person's ability to move, speak and breathe. It advances differently in every patient. Now, ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...

Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more. This ...

ALS is characterized by the death of motor neurons, leading to progressive muscle weakness and loss of voluntary movement. Sporadic ALS accounts for approximately 90-95% of cases, while familial ALS ...

Amyotrophic lateral sclerosis remains difficult to diagnose and is frequently identified after substantial disease progression, underscoring the need for earlier recognition and expanded therapeutic ...

Bill Janes is on a mission to improve life for people with amyotrophic lateral sclerosis (ALS). As a licensed occupational therapist and researcher at the University of Missouri, he's seen firsthand ...